Psyence biomedical ltd.PBM.US Overview
PBM Overall Performance
PBM AI Analysis & Strategy
PBM Recent Performance
-3.02%
Psyence biomedical ltd.
0.81%
Avg of Sector
-1.14%
S&P500
PBM PowerScanner
PBM Key Information
PBM Valuation Metrics
PBM Earnings Table
PBM Profile
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.